Rocket Pharmaceuticals

Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ)

Rocket Pharmaceuticals (RCKT) stock gains as Needham upgrades the company to Buy after FDA alignment on a pivotal Phase 2 trial for a Danon disease.drug. Read more here.

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.

Rocket Pharmaceuticals at Morgan Stanley conference: danon trial clears key hurdle

Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights

The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.

Rocket Pharmaceuticals stock jumps on FDA trial alignment